Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma

Bernd Kasper, MD, PhD
Published: Friday, Mar 17, 2017



Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.

There are 4 studies which used imatinib, explains Kasper. The most positive results from those studies demonstrate a treatment duration of 2 years and an overall response rate of 90%.

There is a retrospective study with sorafenib (Nexavar), which determined an overall response rate of 80% but demonstrated more toxicities than imatinib for patients being treated with sarcoma.
 


Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.

There are 4 studies which used imatinib, explains Kasper. The most positive results from those studies demonstrate a treatment duration of 2 years and an overall response rate of 90%.

There is a retrospective study with sorafenib (Nexavar), which determined an overall response rate of 80% but demonstrated more toxicities than imatinib for patients being treated with sarcoma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x